

1 **Full Title:** Immune and pathophysiologic profiling of antenatal COVID-19 in the GIFT cohort: A  
2 Singaporean case-control study.

3 **Short Title:** Immune consequences and pathophysiology of antenatal COVID-19

4

5 Yue Gu<sup>1,2¶</sup>, Jia Ming Low<sup>3,4¶</sup>, Jolene S.Y. Tan<sup>5¶</sup>, Melissa Shu Feng Ng<sup>6</sup>, Lisa F.P. Ng<sup>7</sup>,

6 Bhuvaneshwari D/O Shunmuganathan<sup>1,2</sup>, Rashi Gupta<sup>1,2</sup>, Paul A. MacAry<sup>1,2</sup>, Zubair Amin<sup>3,4</sup>, Le Ye

7 Lee<sup>3,4</sup>, Derrick W.Q. Lian<sup>8</sup>, Lynette Pei-Chi Shek<sup>4,9</sup>, Youjia Zhong<sup>4,5,9\*</sup>, Liang Wei Wang<sup>6</sup>

8

9 <sup>1</sup>Antibody Engineering Programme, Life Sciences Institute, National University of Singapore,  
10 Singapore

11 <sup>2</sup>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National  
12 University of Singapore, Singapore

13 <sup>3</sup>Department of Neonatology, Khoo Teck Puat-National University Children's Medical Institute,  
14 National University Health System, Singapore

15 <sup>4</sup>Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore,  
16 Singapore

17 <sup>5</sup>Duke-NUS Medical School, Singapore

18 <sup>6</sup>Singapore Immunology Network, Agency for Science, Technology and Research, Singapore

19 <sup>7</sup>Infectious Diseases Labs, Agency for Science, Technology and Research, Singapore

20 <sup>8</sup>Department of Pathology, National University Hospital, Singapore

21 <sup>9</sup>Khoo Teck Puat-National University Children's Medical Institute, National University Health  
22 System, Singapore

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23

24 \*Corresponding author:

25 Email: [youjia\\_zhong@nuhs.edu.sg](mailto:youjia_zhong@nuhs.edu.sg) (YZ)

26

27 ¶These authors contributed equally to this work.

## 28 **Abstract**

### 29 **Background**

30 COVID-19 has been a major public health threat for the past two years, with disproportionate effects  
31 on the elderly, immunocompromised, and pregnant women. While much has been done in delineating  
32 immune dysfunctions and pathogenesis in the former two groups, less is known about the disease's  
33 progression in expectant women and children born to them. To address this knowledge gap, we profiled  
34 the immune responses in maternal and child sera as well as breast milk in terms of antibody and cytokine  
35 expression and performed histopathological studies on placentae obtained from mothers convalescent  
36 from antenatal COVID-19.

### 37 **Methods and findings**

38 A total of 17 mother-child dyads (8 cases of antenatal COVID-19 and 9 healthy unrelated controls; 34  
39 individuals in total) were recruited to the Gestational Immunity For Transfer (GIFT) study. Maternal  
40 and infant sera, and breast milk samples were collected over the first year of life. All samples were  
41 analyzed for IgG and IgA against whole SARS-CoV-2 spike protein, the spike receptor-binding domain  
42 (RBD), and previously reported immunodominant epitopes, with conventional ELISA approaches.  
43 Cytokine levels were quantified in maternal sera using multiplex microbead-based Luminex arrays. The  
44 placentae were examined microscopically. We found high levels of virus-specific IgG in convalescent  
45 mothers and similarly elevated titers in newborn children. Virus-specific IgG in infant circulation waned  
46 within 3-6 months of life. Virus-specific IgA levels were variable among convalescent individuals' sera  
47 and breast milk. Convalescent mothers also showed a blood cytokine signature indicative of a persistent  
48 pro-inflammatory state. Four placentae presented signs of acute inflammation marked by neutrophil  
49 infiltration even though >50 days had elapsed between virus clearance and delivery. Administration of  
50 a single dose of BNT162b2 mRNA vaccine to mothers convalescent from antenatal COVID-19  
51 increased virus-specific IgG and IgA titers in breast milk.

## 52 **Conclusions**

53 Antenatal SARS-CoV-2 infection led to high plasma titres of virus-specific antibodies in infants  
54 postnatally. However, this was not reflected in milk; milk-borne antibody levels varied widely.  
55 Additionally, placentae from COVID-19 positive mothers exhibited signs of acute inflammation with  
56 neutrophilic involvement, particularly in the subchorionic region. Virus neutralisation by plasma was  
57 not uniformly achieved, and the presence of antibodies targeting known immunodominant epitopes did  
58 not assure neutralisation. Antibody transfer ratios and the decay of transplacentally transferred virus-  
59 specific antibodies in neonatal circulation resembled that for other pathogens. Convalescent mothers  
60 showed signs of chronic inflammation marked by persistently elevated IL17RA levels in their blood. A  
61 single dose of the Pfizer BNT162b2 mRNA vaccine provided significant boosts to milk-borne virus-  
62 specific antibodies, highlighting the importance of receiving the vaccine even after natural infection  
63 with the added benefit of enhanced passive immunity. The study is registered at [clinicaltrials.gov](https://clinicaltrials.gov) under  
64 the identifier NCT04802278.

65

## 66 **Introduction**

67 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus  
68 disease 2019 (COVID-19), has infected over 497 million worldwide (WHO website, as of 13<sup>th</sup> April  
69 2022) and led to a pandemic. In the midst of this unprecedented crisis, studies on vulnerable groups  
70 such as pregnant women and newborns are limited compared to the general adult population. Although  
71 the manifestation of COVID-19 is less severe in the paediatric population compared to adults, infants  
72 are particularly susceptible to developing severe illness [1]. Additionally, concerns over mother-to-child  
73 transmission of the virus have led to variable recommendations on postnatal care [2]. Human breast  
74 milk (BM) is the main source of nutrients and bioactive factors that protects infants against general  
75 infections [3]. Maternal antibodies which are present in abundance in BM are able to confer protection

76 against specific infections through their antigen specificity. These maternal antibodies comprise of  
77 approximately 90% immunoglobulin A (IgA), 8% IgM and 2% IgG [4]. SARS-CoV-2 antibodies from  
78 convalescent COVID-19 plasma have been extensively studied as a therapeutic option against COVID-  
79 19 infection [5,6]. Several studies have also reported the presence of SARS-CoV-2 antibodies in the  
80 BM of convalescent COVID-19 mothers [7-9]. However, the durability of those antibodies in the BM  
81 and the mechanism of protection remains incompletely known. Hence, we sought to evaluate the  
82 durability and neutralization capacity of SARS-CoV-2 specific IgG and IgA in the BM of convalescent  
83 COVID-19 mothers.

84 Here, we report that natural infection of pregnant women by SARS-CoV-2 induced antibody  
85 production and secretion into maternal blood and milk. However, plasma antibody titres were not  
86 closely reflected by that in milk. Placentae from COVID-19 positive mothers exhibited signs of acute  
87 inflammation with neutrophilic involvement, despite virus clearance in the nasopharynx. Virus  
88 neutralisation by plasma was not uniformly achieved, despite high levels of antibodies targeting the  
89 spike protein and its receptor-binding domain; the presence of antibodies targeting known  
90 immunodominant epitopes did not assure neutralisation. Antibody transfer ratios and decay kinetics of  
91 virus-specific antibodies in neonatal circulation largely resembled that described for other pathogens.  
92 Targeted analysis of blood cytokines revealed significant elevations in IL17RA levels in convalescent  
93 mothers' blood at 16 weeks (range 13-48) from the initial COVID-19 infection, indicating chronic  
94 inflammation. Importantly, we also found that a single regular dose of the Pfizer BNT162b2 mRNA  
95 vaccine given postnatally boosted milk-borne virus-specific IgG and IgA in mothers convalescent  
96 from antenatal COVID-19.

## 97 **Materials and methods**

### 98 **Ethics statement**

99 This study was approved by the National Healthcare Group Institutional Review Board (Gestational  
100 Immunity For Transfer GIFT: DSRB Reference Number: 2020/00483). Written informed consent was

101 obtained from all subjects (and where applicable, parents), and the study was conducted in accordance  
102 with the Helsinki Declaration. The study protocol was registered at [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04802278).

### 103 **Collection of human breast milk**

104 Breast milk from study participants were collected at 1 month and 3 months postpartum. Milk samples  
105 were aliquoted and frozen at -20 degrees Celsius until use. Recruited mothers who were convalescent  
106 from antenatal COVID-19 (n=8 provided blood samples; n=6 provided BM samples) were confirmed  
107 to be positive for COVID-19 infection with real-time reverse-transcriptase polymerase-chain-reaction  
108 (RT-PCR) assay on nasopharyngeal swabs during pregnancy. Recovery was defined by the resolution  
109 of clinical symptoms and two negative SARS-CoV-2 RT-PCR swabs 24 hours apart. Infants born to  
110 antenatal COVID-19 convalescent mothers at gestational age between 35 to 40 weeks gestation were  
111 included. Mother-child control dyads (n=10) were also recruited. These control mothers had no clinical  
112 symptoms of COVID-19 infection and were confirmed to have a negative SARS-CoV-2 IgG at the time  
113 of recruitment.

### 114 **Blood processing for plasma**

115 Venous blood samples from the infant were collected at 0-3 days, 1 month, and 3 months of life, and  
116 from the mothers at 1 month postpartum, in BD Vacutainer cell preparation tubes (BD, #362753). The  
117 plasma fraction was harvested after centrifugation at 1500rpm, 5 minutes at 4°C and stored at -80°C.  
118 Sample viral inactivation was performed by treatment with 1% Triton X-100 (Thermo Fisher Scientific,  
119 #28314) and 0.3% (w/w) tri-(*n*-butyl) phosphate (TNBP) at room temperature for 2 hours.

### 120 **Synthesis of the SARS-CoV-2 receptor binding domain (RBD) and** 121 **spike protein**

122 SARS-CoV-2 spike and RBD were generously provided by the Antibody Engineering Programme, Life  
123 Sciences Institute, NUS as described previously [10].

## 124 **Spike and RBD-protein based ELISAs**

125 IgA and IgG against SARS-CoV-2 antigens including the whole spike and RBD protein were titrated  
126 using quantitative ELISA. 96-well flat-bottom maxi-binding immunoplate (SPL Life Sciences, #32296)  
127 were coated with 100 ng of SARS-CoV-2 whole spike protein or 200ng of RBD protein at 4 °C  
128 overnight. After three washes in Phosphate Buffer Saline (PBS), 350 µL of blocking buffer [4% skim  
129 milk in PBS with 0.05% Tween 20 (PBST)] was added to each well. After incubation for 1.5 hours, the  
130 plate was washed three times with PBST. 100 µL of 10-times diluted human milk samples, or 100-times  
131 diluted human plasma samples were added to each well for 1-hour incubation. Plate was then washed  
132 three times with PBST followed by 1-hour incubation in the dark with 100 µL of 5000-times diluted  
133 goat anti-human IgG-HRP (Invitrogen, #31413), or 5000-times diluted F(ab')<sub>2</sub> anti-human IgA-HRP  
134 (Invitrogen, #A24458). Plate was washed three times in PBST and incubated for 3 minutes with 1-Step  
135 Ultra TMB-ELISA (Thermo Scientific, #34029), 100 µL per well. Reaction was stopped with 100 µL  
136 of 1 M H<sub>2</sub>SO<sub>4</sub> and optical density at 450nm (OD<sub>450</sub>) was measured using a microplate reader (Tecan  
137 Sunrise). OD<sub>450</sub> was calculated by subtracting the background signal from sample binding to the  
138 blocking buffer. Experiments were performed at least three times.

## 139 **Pseudovirus neutralization test (PVNT)**

140 The PVNT assay was conducted as described previously [11]. Briefly, the ACE2 stably expressed CHO  
141 cells were cultured at 5 × 10<sup>4</sup>/mL cells in complete medium for 24 hours. 80-times diluted plasma were  
142 incubated with 50,000 lentiviral particles (representative of the SARS-CoV-2 Wuhan-Hu-1 strain) in a  
143 total volume of 50 µL at 37 °C for 1 hour. This mixture was added to the CHO-ACE2 monolayer cells  
144 and left incubated for 1 hour to allow pseudotyped viral infection. Subsequently, complete medium was  
145 added at 150 µL/well for further incubation of 48 hours. After two washes with PBS, 100 µL of ONE-  
146 glo™ EX luciferase assay reagent (Promega, #E8130) was added to each well and the luminescence  
147 values were recorded. The percentage neutralization was calculated as follows:

$$148 \quad \text{Neutralization\%} = \frac{\text{Readout (unknown)} - \text{Readout (infected control)}}{\text{Readout (uninfected control)} - \text{Readout (infected control)}} \times 100\%$$

## 149 **Breastmilk/plasma inactivation and peptide based ELISA**

150 Both plasma and BM samples were inactivated with Triton™ X-100 (ThermoFisher Scientific, #28314)  
151 to a final concentration of 1% for 2 hours at room temperature (RT). A focused epitope screen was  
152 performed according to a previously described peptide-based ELISA [12]. S14P5, S20P2, S21P2 and  
153 N4P5 are 18-mer peptides derived from SARS-CoV-2 spike protein with immunodominant activities  
154 [12,13]. For BM ELISA, Streptavidin coated plates (Life Technologies Pierce, #15126) were coated  
155 overnight at 4 degrees with 10 µg/ml peptides diluted in 0.01% polyvinyl alcohol (PVA). Plates were  
156 blocked with 0.01% PVA at RT prior to the addition of BM at 1:10 dilution. Goat HRP-conjugated anti-  
157 human IgA (Abcam, #ab97215) diluted at 1: 2,000 in the blocking buffer was used for the detection of  
158 peptide specific antibodies. TMB substrate (eBioscience, #00-4201-56) was added to the plate for  
159 development and the reaction was quenched with 2M sulfuric acid. Absorbance measurements were  
160 read at two wavelengths (450nm and 570nm) using the Infinite M200 plate reader (Tecan, firmware  
161 V\_2.02\_11/06). Plates were incubated at RT for one hour on a rotating shaker for all steps unless  
162 otherwise stated and washed thrice with 0.1% PBST in between steps.

163 For plasma ELISA, Maxisorp plates (Thermofisher Scientific, #442404) were coated overnight at 4  
164 degrees with 1 µg/ml of Neutraavidin (ThermoFisher Scientific, #31050) diluted in PBS. Plates were  
165 blocked with 0.01% PVA followed by the addition of 1:100 inactivated plasma samples. The subsequent  
166 steps followed the same sequence as mentioned above.

## 167 **Multiplex microbead-based immunoassay**

168 Quantification of cytokine levels in the plasma samples of convalescent and healthy mothers was  
169 performed by multiplex microbead-based immunoassays. Plasma samples were treated with 1%  
170 Triton™ X-100 solvent detergent for virus inactivation [14]. Concentrations of immune mediators were  
171 determined using the Luminex™ assay (HCYTOMAG-60K-41plex) (Millipore Merck). Plasma from  
172 participants (n=7 from each group) and standards were incubated with fluorescent-coded magnetic  
173 beads pre-coated with capture antibodies in a 96-well plate. Biotinylated detection antibodies were



174 incubated with the cytokine-bound beads for an hour. Streptavidin-PE was then added for another 30  
175 mins before the acquisition of data using xPONENET<sup>®</sup> 4.0 (Luminex Corporation, USA) software. Data  
176 was analysed using the Bio-Plex Manager<sup>™</sup>6.1.1. Standard curves were generated with a 5-PL (5-  
177 parameter logistic) algorithm, reporting values of median fluorescence intensity (MFI) and  
178 concentration data.

179 Real time reverse transcriptase polymerase chain reaction (RT-PCR) for COVID-19 PCR swabs were  
180 obtained from amniotic fluid, umbilical cord, placental, umbilical cord blood, maternal blood and high  
181 vaginal swabs and breast milk [15,16].

182 The placenta specimen was fixed in formalin overnight before representative sections were obtained  
183 from the umbilical cord, placental membranes and placental disc. The tissue was subsequently  
184 processed and stained with hematoxylin and eosin for microscopic examination.

## 185 **Statistical Analysis**

186 The OD of samples obtained by subtracting the background signals and normalizing the samples against  
187 a negative control to account for interpolate variations. Data analyses were performed using GraphPad  
188 Prism (GraphPad Software, version 7.0.0). Unless otherwise stated, statistical significance is defined as  
189 p-values being less than 0.05.

## 190 **Results**

### 191 **Clinical demographics of the GIFT cohort**

192 Eight women with a diagnosis of laboratory confirmed COVID-19 during pregnancy participated in the  
193 study (S1 Table). Nine women with no antenatal COVID-19 were recruited as controls. On average,  
194 COVID-19 convalescent women were  $30.3 \pm 2.4$  years old. Additional characteristics of the study  
195 participants and their infants are presented in Table 1. Of the 8 women, 6 had mild COVID-19, with the  
196 most common being dry cough, sore throat and malaise, with one having moderate COVID-19 and the  
197 remaining person being asymptomatic. None of them progressed towards hypoxia or exhibited signs of

198 lower respiratory tract infection (LRTI) evidenced by chest X-ray abnormalities. Consequently, none  
 199 of the subjects required intensive care unit admission, had oxygen requirements, or were intubated.  
 200 Individual clinical demographics of the convalescent women are listed in S2 Table. Extensive testing  
 201 of placental and umbilical cord samples as well as infant throat swabs all produced negative PCR results  
 202 for COVID-19 (detailed reporting of results in S3 Table).

203 **Table 1. Demographic and clinical characteristics of the cohort.**

<b>Maternal Characteristics</b>	<b>Cases (n=8)</b>	<b>Controls (n=9)</b>
Age (average; years) (standard deviation, SD)	30.3 ± 2.4	32.1 ± 2.5
<b>Race/ethnicity:</b>		
Chinese	1	6
Malay	3	2
Indian	2	1
Caucasian	2	0
BMI (SD)	27 ± 2.2	25.7 ± 1.5
No past medical history	7	8
Other co-morbidities if any		
- Hepatitis C carrier	1	2
- Gestational diabetes mellitus (GDM)	0	1

- Smoking	1	1
- Pre-eclampsia	0	0
Antenatal fetal anomaly scan	No abnormalities detected	No abnormalities detected
Occurrence of mastitis during the study period	0	0
<b>Timing of COVID-19 infection:</b>		
First trimester	2	-
Second trimester	2	-
Third trimester	4	-
<b>Severity</b>		
Symptomatic	6 mild, 1 moderate	-
Asymptomatic	1	-

204


<b>Infant Characteristics</b>	<b>Cases (n=8)</b>	<b>Controls (n=9)</b>
Female	6	6
Gestational age when born (weeks) (SD)	39 ± 2	39 ± 1
<b>Growth at birth:</b>		
Birth weight (kg) (SD)	3.517 ± 0.261	3.108 ± 0.376

Length (cm) (SD)	50.5 ± 1.2	50.6 ± 1.3
Occipital frontal circumference (cm) (SD)	34.5 ± 0.7	33.3 ± 0.7
<b>Breastfeeding status:</b>		
Exclusive	6	9
Mixed feeding	2	0

205

206 The eight infants were all born full term with mean gestational age (SD) of  $39 \pm 2$  weeks and had a  
207 mean birth weight (SD) of  $3.517 \pm 0.261$  kg. One infant required neonatal intensive care unit stay for 2  
208 days for transient tachypnea of the newborn and was given supplemental oxygen therapy. All infants  
209 were breastfed up to 3 months, two of whom were supplemented with formula milk during the same  
210 period.

211 It remains controversial whether SARS-CoV-2 can be vertically transmitted and if so, what damage it  
212 might cause to the developing child and the maternal-foetal interface i.e., the placenta, especially in  
213 continued pregnancy post convalescence from antenatal COVID-19 [17-19]. To address that question,  
214 histological examination of placental samples was done to determine if there were notable pathologies  
215 or abnormalities. While all 8 samples did not show the presence of SARS-CoV-2, three placentae (CS02,  
216 CS03, CS07) showed signs of acute inflammation (Fig 1). Neutrophils were seen in the subchorionic  
217 fibrin, indicating subchorionitis. There was no spread of the neutrophils into the chorion or amnion. A  
218 mild corresponding foetal inflammatory response was also seen in the umbilical arteries and veins of  
219 one of the placentas (CS03). The placenta of CS05 had signs of maternal-foetal malperfusion, and this  
220 placenta was also hypoplastic at 389g at 38+0 weeks gestation). However, CS05 had concomitant  
221 gestational diabetes mellitus.



222


223 **Fig 1. Neutrophilic infiltration present in the placental of convalescent mothers.** Microscopic  
224 analysis shows a neutrophilic infiltrate in the subchorionic region of the placenta of three patients - (A)  
225 patient CS2, H&E x 100, (B) patient CS3, H&E x100, (C) patient CS7, H&E x100. (D) Higher power  
226 view of the inflammatory process (patient CS2, H&E x200).

227

## 228 **Convalescent mothers carry SARS-CoV-2 specific antibodies in** 229 **their blood**

230 We first confirmed the presence of IgG antibodies targeting SARS-CoV-2 spike protein (Fig 2A) and  
231 spike protein RBD (Fig 2B) in all mothers' plasma 1-month post-partum. Plasma IgA antibodies  
232 targeting the same antigens were expressed more variably; they were detected in ~50% of the  
233 convalescent mothers (Fig 2C, D).

234



235

236 **Fig 2. Spike and RBD-specific IgG and IgA present in maternal plasma of convalescent mothers.**

237 Using a protein-based ELISA, maternal plasma from control (CT01- CT10) and convalescent (CS01-

238 CS07) mothers obtained 1-month post-partum were used for the detection of spike (A and C) and RBD

239 (B and D) specific IgG and IgA antibodies. The bar graphs represent the normalized average signals of

240 antibodies binding to the respective proteins. Convalescent mothers (CS samples) are arranged in

241 ascending order according to their time from COVID diagnosis to delivery.

242

243 Most convalescent maternal plasma were able to neutralize SARS-CoV-2 pseudoviruses, albeit to

244 varying extents (Fig 3). Interestingly, plasma from one mother – CS04 – showed no detectable

245 pseudovirus neutralizing ability despite spike- and RBD-specific IgG antibodies being present and


246 comparable to other convalescent mothers. These antibodies are likely to confer some degree of

247 protection against SARS-CoV-2 infections. It is worth noting that neutralization capacity did not

248 correlate with the length of time between disease resolution and point of sampling. In other words, the

249 women who were infected at an earlier stage of pregnancy did not necessarily produce lower titers as

250 one would expect due to antibody decay and contraction of the humoral response.



251

252 **Fig 3. Neutralization of SARS-CoV-2 pseudovirus using maternal plasma.** Plasma from control  
253 (n=10) and convalescent mothers (n=7). Bar graphs represent the average percentage neutralization.  
254 Convalescent mothers (CS samples) are arranged in ascending order according to their time from  
255 COVID diagnosis to delivery.

256


257 Four immunodominant epitopes S14P5, S20P2, S21P2 and N4P5 were previously identified to be  
258 associated with disease severity in adults (age  $41 \pm 13$ , years  $\pm$  standard deviation) [12]. Importantly,  
259 antibodies against S14P5 and S21P2 epitopes were able to neutralize SARS-CoV-2-infection  
260 [12,13,20]. Hence, we evaluated the presence of antibodies against the four immunodominant epitopes  
261 in our cohort. A significant increase in the levels of IgG against S21P2 (Mann Whitney, two tailed,  
262  $p=0.0205$ ) was observed in the plasma of convalescent mothers compared to controls (S1 Fig C). No  
263 significant difference in the levels of IgG against the other three immunodominant epitopes in the  
264 plasma of convalescent mothers compared to controls was found (S1 Fig A, B, and D). The IgA levels  
265 against the four immunodominant epitopes in convalescent mothers were mostly below the limit of  
266 detection. Hence differences in IgA levels in the plasma between both groups cannot be accurately  
267 determined (S2 Fig).

268 **SARS-CoV-2 specific antibodies transferred in-utero to the child**

269 **wanes over 6 months**

270 An important component of passive immunity is the suite of antibodies transferred across the placenta  
271 from mother to child. As shown in Fig 4A and B, compared to the mothers, SARS-CoV-2 specific IgG  
272 antibodies were detected in the infants' sera at comparable or higher levels at birth, showing passive  
273 immunity to be successfully transferred via the placenta. We observed a steady decrease in plasma IgG  
274 levels in infants from birth to 6 months of age, where the signal approached the lower detection limit.  
275 The transplacental transfer ratios for spike- and RBD-specific IgG antibodies ranged from 0.73 to 1.4  
276 6 (Fig 4C and D), in alignment with previous COVID-19 studies and other types of pathogens [21-23].





277

278 **Fig 4. Spike and RBD-specific IgG are passively transferred from convalescent mothers to infants.**

279 (A) Spike and (B) RBD-specific IgG from maternal plasma 1 month post-partum and at three time

280 points from babies' plasma was determined using ELISA. Transfer ratio at the 1 month timepoint of


281 (C) spike and (D) RBD-specific IgG from mother to infant was calculated by taking the averaged IgG

282 signal of baby's over the mother's IgG. Convalescent mothers (CS samples) are arranged in ascending  
283 order according to their time from COVID diagnosis to delivery.

284

285 **SARS-CoV-2 specific antibodies are not appreciably secreted into**  
286 **convalescent milk**

287 Apart from transplacental transfer of antibodies, another important mechanism of transmitting passive  
288 immunity to the child is via BM. Hence, we sought to measure virus-specific antibody titers in milk of  
289 mothers convalescent from antenatal COVID-19. Generally, minimal SARS-CoV-2 spike- and RBD-  
290 specific IgG and IgA antibodies were present in milk at 0-3 months postpartum (Fig 5). The same was  
291 observed for the epitope-specific antibodies (S3 Fig).



292

293 **Fig 5. Spike and RBD-specific IgA present in maternal breast milk of convalescent mothers.** Using  
294 a protein-based ELISA, maternal breast milk from control (CT01- CT10) and convalescent (CS01-  
295 CS08) mothers obtained at two time points 0-1months and 2-3months post-partum were used for the  
296 detection of spike and RBD-specific IgG and IgA antibodies. Breast milk was screened for (A) spike-  
297 specific IgG, (B) RBD-specific IgG, (C) spike-specific IgA, and (D) RBD-specific IgA. The bar graphs  
298 represent the normalized average signals of antibodies binding to the respective proteins. Convalescent  
299 mothers (CS samples) are arranged in ascending order according to their time from COVID diagnosis  
300 to delivery.


301

302 We noted a singular case, CS04, who produced S21P2-specific IgA responses in plasma and milk that  
303 were significantly higher than others, with no decrease observed up to 3 months postpartum (S2 Fig C,  
304 S3 Fig C). Notably, CS04 suffers from chronic high-viral load hepatitis C virus (HCV) infection, where

305 the virus is of genotype GT3a. CS04 did not have unusually high serum IgA (Fig 2C and D). Hence,  
306 we asked the question whether HCV genotype GT3a encodes S21P2-like antigens that could induce  
307 cross-reactive antibody production. Initial Protein BLAST revealed no significant overlap between  
308 S21P2 and HCV proteins, including those encoded by GT3a (S1 Appendix). We then compared CS04  
309 against CT10, a control mother who was COVID-19-negative but was HCV genotype GT3a-positive  
310 with comparable viral loads. Unlike CS04, CT10 did not have any pre-existing antibodies against S21P2  
311 (S2 Fig C, S3 Fig C). This suggests that the high titers of S21P2-specific IgA in CS04 were not due to  
312 cross-reactive IgA-mediated immunity against HCV. It might be that carriage of HCV results in a  
313 stronger mucosa-directed anti-viral response marked by higher titers of anti-S21P2 IgA. Nonetheless,  
314 we acknowledge the key limitation of small sample size, given the rarity of co-infections by SARS-  
315 CoV-2 and HCV in pregnant women; larger studies will be required to clarify interactions or lack  
316 thereof between the two viruses.

### 317 **Persistence of pro-inflammatory cytokines in convalescent mothers**

318 To gain insight on long-term perturbations in the maternal immune system post-COVID 19, we  
319 quantified levels of cytokines with a 41-plex microbead-based immunoassay. Using plasma samples of  
320 six control and seven convalescent mothers at 1-month post-partum, we could detect 33 out of 41  
321 cytokines (Fig 6). As far as the assayed cytokines were concerned, both healthy and convalescent  
322 mothers had largely similar signatures. Most of the signals for the detected cytokines were not  
323 distributed normally, likely due to the fact that they clustered near the lower limit of detection.  
324 Notwithstanding, five cytokines, namely interleukin-17RA (IL-17RA), eotaxin, interferon-gamma  
325 produced protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1) and macrophage  
326 inflammatory protein-1 $\beta$  (MIP-1 $\beta$ ) exhibited Gaussian distributions and were likely more robust  
327 biomarkers. Hence, we focused on these cytokines for further analysis. In order to detect cytokines with  
328 increased expression in convalescent mothers, we utilized a statistical threshold of  $p < 0.1$  due to small  
329 sample size and low power in this study. We found that pro-inflammatory cytokines IL-17RA ( $p = 0.02$ )  
330 and MCP-1 ( $p = 0.0766$ ) were elevated in convalescent mothers than healthy controls, suggestive of a  
331 prolonged inflammatory state long after COVID resolution (Fig 6B and C).




332

333 **Fig 6. Cytokine profile differences in healthy and convalescent mothers' plasma.** Using 1-month  
 334 post-partum plasma (n=6 for controls and n=7 for cases), cytokines were evaluated using the 41-plex  
 335 Luminex™ assay. (A) A representation of all cytokines that were detected, (B) IL-17RA levels and (C)  
 336 MCP-1. Convalescent mothers are represented in red while healthy controls are represented in black.  
 337 Bar graphs represent the average log(concentration) from the samples from the respective groups in A  
 338 while the measured concentrations were used for B and C.

339

340 **SARS-CoV-2 specific antibody titers in convalescent milk are**  
 341 **boosted with a single dose of Pfizer/BioNTech's BNT162b2**  
 342 **mRNA vaccine**

343 Given the observation that IgG transferred via the placenta only lasted for about 6 months in the  
344 infant, and the scarcity of SARS-CoV-2 specific antibodies in convalescent milk, we investigated  
345 alternative methods of passive immunity to protect infants from potential SARS-CoV-2 infection.  
346 Three convalescent mothers from our original cohort who were still nursing were given one dose of  
347 the BNT162b2 (Pfizer/BioNTech) mRNA vaccine. BM was taken at 4 time points, namely before  
348 vaccination, 3 days post-vaccination (PV), 7 days PV and 30 days PV. SARS-CoV-2 specific  
349 antibodies were not detectable in milk before vaccination. At 7-30 days PV, both SARS-CoV-2  
350 specific IgG and IgA were generally detected at much higher levels (Fig 7), although CS11 did not  
351 secrete detectable levels of RBD-specific IgA into her milk (Fig 7B).



352  
353 **Fig 7. Increased secretion and production of spike-specific IgA and IgG antibodies post-**  
354 **vaccination in convalescent mothers.** Breast milk from three nursing convalescent mothers were  
355 collected at 4 time points, prior to vaccination (0), 3 days post-vaccination, 7 days post-vaccination,

356 and 30 days post-vaccination for a (A and C) spike and (B and D) RBD protein-based IgA and IgG  
357 ELISA assay. The x-axis refers to the number of days post-vaccination.

358

## 359 **Discussion**

360 In this study, we show that women who had acquired COVID-19 during pregnancy have high levels  
361 of circulating virus-specific IgG in their blood relative to control mothers. Furthermore, spike- and  
362 RBD-specific IgG levels in maternal circulation were maintained at relatively high levels regardless  
363 of gestation when SARS-CoV-2 infection was acquired in pregnancy; virus-specific IgG could be  
364 detected in infants at birth when mothers had acquired antenatal COVID-19 as early as 15 weeks.  
365 However, circulating spike- and RBD-specific IgG levels in infants born to convalescent COVID-19  
366 mothers declined to negligible levels by three months of life. These findings are all consistent with the  
367 known patterns of acute gestational infections and passive immunity.

368 While virus-specific IgG was robustly expressed in convalescent plasma, virus-specific IgA levels in  
369 the blood were far more variable. IgA is a marker of acute infection and wanes just as IgG expression  
370 starts to pick up during disease resolution [24,25]. Hence, the expectation is that the shorter the  
371 interval between virus clearance and the point of sampling, the higher the IgA titers measured at the  
372 time of sample collection. We did not see such a clear pattern, which may be due to our small sample  
373 size and other factors related to host genetics and the environment that may modulate the plasma IgA  
374 response.

375 It is worth noting that, of the placental samples examined, CS02, CS03 and CS07 showed up  
376 abnormal findings indicative of acute inflammation, more than 50 days after their nasopharyngeal  
377 swab tested negative by PCR. These findings are broadly consistent with previous studies  
378 documenting acute inflammatory pathology, maternal vascular malperfusion, fibrinoid changes and  
379 macrophage infiltration [26,27]. Most of the literature on placental pathology in the context of

380 COVID-19 in pregnancy look mainly at acute perinatal infection - trophoblast necrosis and chronic  
381 histiocytic intervillitis are common in cases of vertical transmission, whereas materno-foetal  
382 malperfusion and villitis are common where there is no vertical transmission. To our knowledge, there  
383 are no reports of placental pathology in women convalescent from antenatal COVID-19 at the point of  
384 delivery. Interestingly, the four convalescent mothers whose placentae showed abnormal  
385 characteristics also showed the lowest titers of virus-specific IgA in their blood. Plasma IgA is  
386 predominantly monomeric and capable of engaging Fc $\alpha$ RI (also known as CD89) on myeloid cells,  
387 presumably to trigger the first line of anti-viral defense. One may speculate that placental  
388 granulocytes perform a largely sentinel role to prevent compromise of the placental barrier, and in the  
389 absence of high amounts of plasma IgA indicative of active infection, they might be continually and  
390 preferentially mobilized to the placenta leading to low levels in the circulation [28].

391 Inefficient transplacental antibody transfer has been previously reported in a small cohort study of  
392 COVID-19 mothers [22]. However, we did not see this particular effect in our cohort, even in the  
393 mothers who acquired COVID-19 in the third trimester and whose placentae exhibited signs of  
394 inflammation and potential tissue damage. These discrepancies might be due to differences in severity  
395 stratification (ratio of asymptomatic: mild: moderate: severe was 6:9:3:4 in Atyeo *et al.* versus 1:6:1:0  
396 in our cohort) and symptom onset to delivery (median of 30.5 days in Atyeo *et al.* versus 98.5 days in  
397 our cohort). Also, transplacental transfer occurs most efficiently late into the third trimester, and so  
398 infections occurring and resolving earlier in the first and second trimesters are less likely to impact  
399 transfer [29].

400 In our study, we noted a significant elevation of IL-17RA and a trend of increased MCP-1 in  
401 convalescent mothers relative to controls (Fig 6B and C). IL-17RA is a soluble receptor of IL-17A,  
402 thereby preventing the latter's association with cell surface receptors. IL-17A has been implicated in  
403 SARS-CoV-2 pathogenesis with elevated peripheral IL-17 levels and Th17 infiltration in the lungs of  
404 COVID patients [30,31]. The persistence of IL-17A together with other inflammatory cytokines such  
405 as IL-12p70, stem cell factor, and IL-1 $\beta$  was discovered in patients up to 180 days post-infection [32].  
406 In agreement with our findings, COVID-19 patients were found to have increased IL-17RA levels



407 during the acute phase, especially in those with milder symptoms [33]. Hence, enhanced IL-17RA  
408 may have a protective role in limiting the downstream effects of IL-17; elevated IL-17RA levels may  
409 be a prognostic marker of mild disease in pregnant and lactating women. MCP-1 is the other cytokine  
410 that was slightly elevated in convalescent mothers relative to control mothers. It is produced by  
411 monocytes and macrophages to regulate the migration and infiltration of natural killer cells,  
412 monocytes, and T cells [34]. Greater MCP-1 expression characterizes patients with mild COVID-19,  
413 suggestive of potential roles in mitigating severity [35]. However, we note that the lack of severe  
414 cases in our cohort limits us from investigating whether high IL-17RA and MCP-1 levels are true  
415 predictors of mild disease.

416 In breast milk, low levels of spike-specific IgG were secreted into 2 out of 8 convalescent women's  
417 BM. This is consistent with the existing dogma that IgG is rarely released into milk; the dominant  
418 isotype is IgA. Even so, virus-specific IgA was only present in a subset of convalescent mothers' milk  
419 samples. This is somewhat expected as IgA levels are not maintained throughout infection and have  
420 been found to be lowest on the outset in mild cases, where most of the subjects in our cohort fall  
421 under [24].

422 We further delineated the humoral response to linear B cell epitopes that have been previously  
423 described to be immunodominant. There are certain advantages in investigating these epitopes instead  
424 of conformational ones – (1) the system is considerably cheaper to set up for further validation  
425 studies, and (2) it is easier to prime cells with peptides which can be synthesized conveniently and do  
426 not require complex purification and refolding protocols. We found that most linear epitopes were  
427 generally not well-recognized by antibodies present in sera and milk from convalescent mothers. This  
428 might be due to the fact that long periods of time had passed between COVID-19 recovery and  
429 sampling points; the antibody levels waned, similar to that for other infections. One notable exception  
430 is S21P2, where epitope-specific IgG was significantly elevated in convalescent plasma compared to  
431 controls. In particular, CS04 produced extremely high levels of S21P2-specific IgA in the BM by  
432 mechanisms unknown to us, although preliminary analysis has excluded HCV antigen cross-reactivity  
433 as one possible factor. Nonetheless, much of these signals were non-specific and could also be

434 detected in controls who had non-SARS-CoV-2 coronavirus infection or non-coronavirus antenatal  
435 URTI.

436 Given that convalescent sera do contain high levels of spike- and RBD-specific IgG and yet exhibit  
437 low, variable neutralization capacities, we infer that most of the IgG are poorly functional in terms of  
438 blocking receptor binding, which is consistent with a previous report showing low neutralizing  
439 antibody titers in mild cases [36]. The current design of the mRNA vaccines utilizes the 2P mutated  
440 spike to stabilize its pre-fusion conformation. As these convalescent women had not received the  
441 vaccine prior to infection, their immune systems likely encountered virions that had a mix of pre-  
442 fusion and post-fusion trimers, the latter having evolved to perhaps fulfil immunoevasive functions  
443 [37]. The consequence for these individuals is the production of weakly neutralizing antibodies that  
444 primarily target the post-fusion conformational epitopes. Had the infected individuals produced  
445 strongly neutralizing antibodies, those antibodies would have been predominantly raised against the  
446 pre-fusion conformation. Given that a single dose of the Pfizer mRNA vaccine was sufficient to boost  
447 virus-specific IgG and IgA responses in mothers who had long convalesced from natural SARS-CoV-  
448 2 infection, we speculate that the booster-elicited antibodies are directed against both the pre- and  
449 post-fusion forms; recall responses are activated in cells recognizing the post-fusion spike, and  
450 primary responses are generated in response to the vaccine-encoded pre-fusion spike. Together, these  
451 findings underscore the importance of receiving the vaccine even after recovery from natural  
452 infection. Additionally, given the lack of safety and efficacy data in administering vaccines to infants,  
453 breastfeeding after vaccination could be a viable alternative to conferring some form of mucosal  
454 immunity to the vulnerable children, after the loss of transplacentally transferred antibodies at 3  
455 months of age.

456 A key limitation of our study is the cohort size. Most of our samples were collected early on in the  
457 pandemic before Singapore introduced a slew of effective public health measures to stymie the spread  
458 of the virus, including travel restrictions, social distancing, and a lockdown. Due to this unique  
459 situation, relatively few people were infected in the first wave from April to August 2020. Limited

460 community transmission between August 2020 and August 2021 prevented further subject recruitment  
461 and sample collection.

462 In the context of the present situation, we note two caveats, namely the current dominance of Delta  
463 and Omicron over early pandemic variants and the high rate of vaccine uptake by the resident  
464 population (~92% as of 31<sup>st</sup> March 2022). These two factors preclude meaningful head-to-head  
465 comparisons of more recent studies against our cohort in the GIFT study where immunologically  
466 naïve individuals were infected with variants possessing lower immunoevasive abilities.

467 Notwithstanding these differences, our studies provide insights into the pathogenesis of COVID-19 in  
468 the under-studied demographics of pregnant and lactating women as well as infants born to them.

## 469 **Author contributions**

470 Y.G. – Formal analysis, Investigation, Methodology, Validation, Writing – Original draft preparation,  
471 Writing – review & editing. J.M.L. – Conceptualization, Formal analysis, Funding acquisition,  
472 Investigation, Project administration, Resources, Validation, Writing – Original draft preparation,  
473 Writing – review & editing. J.S.Y.T. – Formal analysis, Investigation, Methodology, Visualization,  
474 Writing – Original draft preparation, Writing – review & editing. M.S.F.N – Formal analysis,  
475 Investigation, Validation, Writing – Original draft preparation, Writing – review & editing. L.F.P.N –  
476 Methodology, Writing – review & editing. B.N. – Investigation, Methodology, Validation, Writing –  
477 review & editing. R.G. – Investigation, Writing – review & editing. P.A.M – Resources, Supervision,  
478 Writing – review & editing. Z.A. – Resources, Supervision, Writing – review & editing. L.Y.L. –  
479 Funding acquisition, Supervision, Writing – review & editing. D.W.Q.L – Formal Analysis,  
480 Investigation, Methodology, Validation, Supervision, Writing – review & editing. L.P.C.S –  
481 Supervision, Writing – review & editing. Y.Z. – Formal analysis, Investigation, Methodology, Project  
482 administration, Supervision, Validation, Writing – Original draft preparation, Writing – review &  
483 editing. L.W.W. – Formal analysis, Investigation, Methodology, Project administration, Supervision,  
484 Validation, Writing – Original draft preparation, Writing – review & editing.

485 All authors declare that they have no conflicts of interest.

## 486 **Acknowledgements**

487 This work was funded by National University Hospital of Singapore (NUHS) seed grants awarded to  
488 J.M.L. and L.Y.L. L.W.W. is a recipient of the Singapore National Medical Research Council Open  
489 Fund Young Investigator Grant (NMRC OF-YIRG; Grant number MOH-000545-00) and an award  
490 from the A\*STAR Biomedical Research Council (BMRC) Central Research Fund for Use-Inspired  
491 Basic Research (CRF-UIBR).

492 We thank Antibody Engineering Programme, Life Sciences Institute, NUS for providing the purified  
493 spike protein and RBD. We thank Associate professor Tan Yee Joo from Department of Microbiology

494 and Immunology, Yong Loo Lin School of Medicine, NUS for the ACE2 stably expressing CHO cells  
495 and plasmid encoding SARS-CoV-2 S protein for the pseudotyped lentiviral production. We thank the  
496 participating mothers and children for their kind donation of samples.

497

## 498 **References**

- 499 1. Eastin C, Eastin T. Epidemiological characteristics of 2143 pediatric patients with 2019  
500 coronavirus disease in China: Dong Y, Mo X, Hu Y, et al. *Pediatrics*. 2020; doi: 10.1542/peds.2020-  
501 0702. *J Emerg Med*. 2020;58(4):712-3.
- 502 2. Kyle MH, Glassman ME, Khan A, Fernández CR, Hanft E, Emeruwa UN, et al. A review of  
503 newborn outcomes during the COVID-19 pandemic. *Semin Perinatol*. 2020;44(7):151286-.
- 504 3. Cacho NT, Lawrence RM. Innate Immunity and Breast Milk. *Frontiers in Immunology*.  
505 2017;8(584).
- 506 4. Demers-Mathieu V, Underwood MA, Beverly RL, Nielsen SD, Dallas DC. Comparison of  
507 Human Milk Immunoglobulin Survival during Gastric Digestion between Preterm and Term Infants.  
508 *Nutrients*. 2018;10(5):631.
- 509 5. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Dynamics and  
510 significance of the antibody response to SARS-CoV-2 infection. *medRxiv : the preprint server for*  
511 *health sciences*. 2020.
- 512 6. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2  
513 in Patients With Novel Coronavirus Disease 2019. *Clinical infectious diseases : an official publication*  
514 *of the Infectious Diseases Society of America*. 2020;71(16):2027-34.
- 515 7. Dong Y, Chi X, Hai H, Sun L, Zhang M, Xie WF, et al. Antibodies in the breast milk of a  
516 maternal woman with COVID-19. *Emerging microbes & infections*. 2020;9(1):1467-9.
- 517 8. Fox A, Marino J, Amanat F, Krammer F, Hahn-Holbrook J, Zolla-Pazner S, et al. Robust and  
518 Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk. *iScience*.  
519 2020;23(11):101735-.
- 520 9. Gao X, Wang S, Zeng W, Chen S, Wu J, Lin X, et al. Clinical and immunologic features  
521 among COVID-19-affected mother-infant pairs: antibodies to SARS-CoV-2 detected in breast milk.  
522 *New microbes and new infections*. 2020;37:100752.

- 523 10. Raghuvamsi PV, Tulsian NK, Samsudin F, Qian X, Purushotorman K, Yue G, et al. SARS-  
524 CoV-2 S protein:ACE2 interaction reveals novel allosteric targets. *eLife*. 2021;10.
- 525 11. Kongsuphol P, Jia H, Cheng HL, Gu Y, Shunmuganathan BDO, Chen MW, et al. A rapid  
526 simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies. *Communications*  
527 *Medicine*. 2021;1(1):46.
- 528 12. Amrun SN, Lee CY, Lee B, Fong SW, Young BE, Chee RS, et al. Linear B-cell epitopes in  
529 the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity.  
530 *EBioMedicine*. 2020;58:102911.
- 531 13. Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY-P, Chee RS-L, et al. Two linear epitopes  
532 on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. *Nature*  
533 *Communications*. 2020;11(1):2806.
- 534 14. Chan YH, Young BE, Fong SW, Ding Y, Goh YS, Chee RS, et al. Differential Cytokine  
535 Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. *Front Immunol*.  
536 2021;12:680188.
- 537 15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected  
538 with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 539 16. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia  
540 associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a  
541 family cluster. *Lancet*. 2020;395(10223):514-523.
- 542 17. Fan C, Guo Y, Qu P, Wang S, Wang M, Yuan J, et al. No obviously adverse pregnancy  
543 complications and outcomes of the recovered pregnant women from COVID-19. *Reproductive*  
544 *toxicology* (Elmsford, NY). 2021;100:163-6.
- 545 18. Sharps MC, Hayes DJL, Lee S, Zou Z, Brady CA, Almoghrabi Y, et al. A structured review  
546 of placental morphology and histopathological lesions associated with SARS-CoV-2 infection.  
547 *Placenta*. 2020;101:13-29.

- 548 19. Di Girolamo R, Khalil A, Alameddine S, D'Angelo E, Galliani C, Matarrelli B, et al.  
549 Placental histopathology after SARS-CoV-2 infection in pregnancy: a systematic review and meta-  
550 analysis. *American journal of obstetrics & gynecology MFM*. 2021;3(6):100468.
- 551 20. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of  
552 COVID-19 patients reveals cross-reactivity and correlates of severity. *Science (New York, NY)*.  
553 2020;370(6520).
- 554 21. Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al.  
555 Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer  
556 Ratios. *JAMA Pediatrics*. 2021;175(6):594-600.
- 557 22. Atyeo C, Pullen KM, Bordt EA, Fischinger S, Burke J, Michell A, et al. Compromised  
558 SARS-CoV-2-specific placental antibody transfer. *Cell*. 2021;184(3):628-42.e10.
- 559 23. Fu C, Lu L, Wu H, Shaman J, Cao Y, Fang F, et al. Placental antibody transfer efficiency and  
560 maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-  
561 1 antibodies. *Scientific Reports*. 2016;6(1):38874.
- 562 24. Zervou FN, Louie P, Stachel A, Zacharioudakis IM, Ortiz-Mendez Y, Thomas K, et al.  
563 SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.  
564 *Journal of medical virology*. 2021;93(9):5409-15.
- 565 25. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in  
566 COVID-19. *Cellular & Molecular Immunology*. 2020;17(7):773-5.
- 567 26. Schwartz DA, Morotti D. Placental Pathology of COVID-19 with and without Fetal and  
568 Neonatal Infection: Trophoblast Necrosis and Chronic Histiocytic Intervillositis as Risk Factors for  
569 Transplacental Transmission of SARS-CoV-2. *Viruses*. 2020;12(11):1308.
- 570 27. Menter T, Mertz KD, Jiang S, Chen H, Monod C, Tzankov A, et al. Placental Pathology  
571 Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion.  
572 *Pathobiology*. 2021;88(1):69-77.



- 573 28. Facchetti F, Bugatti M, Drera E, Tripodo C, Sartori E, Cancila V, et al. SARS-CoV2 vertical  
574 transmission with adverse effects on the newborn revealed through integrated immunohistochemical,  
575 electron microscopy and molecular analyses of Placenta. *EBioMedicine*. 2020;59:102951.
- 576 29. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental  
577 transfer in healthy and pathological pregnancies. *Clinical & developmental immunology*.  
578 2012;2012:985646.
- 579 30. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19  
580 associated with acute respiratory distress syndrome. *The Lancet Respiratory medicine*. 2020;8(4):420-  
581 2.
- 582 31. Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? *Nat Rev Immunol*.  
583 2020;20(6):345-6.
- 584 32. Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. Persistent Symptoms  
585 and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019  
586 Patients. *Open forum infectious diseases*. 2021;8(6):ofab156.
- 587 33. Cacciapuoti S, De Rosa A, Gelzo M, Megna M, Raia M, Pinchera B, et al. Immunocytometric  
588 analysis of COVID patients: A contribution to personalized therapy? *Life Sci*. 2020;261:118355-.
- 589 34. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-  
590 1): an overview. *Journal of interferon & cytokine research : the official journal of the International*  
591 *Society for Interferon and Cytokine Research*. 2009;29(6):313-26.
- 592 35. Xi X, Guo Y, Zhu M, Wei Y, Li G, Du B, et al. Higher expression of monocyte chemotactic  
593 protein 1 in mild COVID-19 patients might be correlated with inhibition of Type I IFN signaling.  
594 *Virology Journal*. 2021;18(1):12.
- 595 36. Chen X, Pan Z, Yue S, Yu F, Zhang J, Yang Y, et al. Disease severity dictates SARS-CoV-2-  
596 specific neutralizing antibody responses in COVID-19. *Signal Transduction and Targeted Therapy*.  
597 2020;5(1):180.
- 598 37. Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM, Jr., et al. Distinct conformational  
599 states of SARS-CoV-2 spike protein. *Science (New York, NY)*. 2020;369(6511):1586-92.